Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer

Oncotarget

Volumn 7, Issue 9, 2016, Pages 9925-9938

  Fan, Yong ^a   Zhou, Xin ^b   Xia, Tian Song ^b   Chen, Zhuo ^a   Li, Jin ^a   Liu, Qun ^a   Alolga, Raphael N ^a   Chen, Yan ^b   Lai, Mao De ^a   Li, Ping ^a   Zhu, Wei ^b   Qi, Lian Wen ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Differential metabolites; Human plasma metabolomics; Molecular subtypes

Indexed keywords

2 OCTENEDIOIC ACID; ALANINE; ALIPHATIC DICARBOXYLIC ACID; ASPARTIC ACID; CARNITINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUTAMIC ACID; GLYCEROLIPID; GLYCOCHENODEOXYCHOLIC ACID; LYSOPHOSPHATIDYLCHOLINE; PROLINE; PURINE; UNCLASSIFIED DRUG; VALINE; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AEROBIC METABOLISM; AGED; AMINO ACID METABOLISM; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CITRIC ACID CYCLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FATTY ACID SYNTHESIS; GLUCONEOGENESIS; GLYCOLYSIS; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; PREDICTION; PROTEIN EXPRESSION; PURINE METABOLISM; BLOOD; BREAST TUMOR; CLASSIFICATION; FEMALE; METABOLISM; METABOLOME; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHROMATOGRAPHY, LIQUID; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84961644536     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7155     Document Type: Article

References (25)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29.
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H and Akslen LA. Molecular portraits of human breast tumours. Nature. 2000; 406:747-752.
3. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A, Deng S, Johnsen H, Pesich R and Geisler S. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences. 2003; 100:8418-8423.
4. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M and Wagner P. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research. 2005; 11:5678-5685.
5. Tsimberidou A-M, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F and Luthra R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clinical Cancer Research. 2012; 18:6373-6383.
6. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K and Haffari G. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012; 486:395-399.
7. Murtaza M, Dawson S-J, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin S-F, Kingsbury Z and Wong AS. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497:108-112.
8. Jin X, Yun JS, Jeong P, Kim YI, Kim WJ, and Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget. 2014; 5: 1636-1645. doi: 10.18632/oncotarget.1744.
9. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ and Li Y. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457:910-914.
10. Nicholson JK, Connelly J, Lindon JC and Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nature reviews Drug discovery. 2002; 1:153-161.
11. Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, Faught W and Sawyer MB. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clinical Cancer Research. 2010; 16:5835-5841.
12. Bales JR, Higham DP, Howe I, Nicholson JK and Sadler PJ. Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. Clinical chemistry. 1984; 30:426-432.
13. Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M and Wang X. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Molecular & Cellular Proteomics. 2011; 10:M110. 004945.
14. Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X, Wang H and Xu G. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer research. 2013; 73:4992-5002.
15. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-14.
16. Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, Chow A, O'Connor STF, Li S and Chin AR. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nature cell biology. 2015; 17:183-194.
17. Currie E, Schulze A, Zechner R, Walther TC and Farese RV. Cellular fatty acid metabolism and cancer. Cell Metabolism. 2013; 18:153-161.
18. Caiazza F, Harvey BJ and Thomas W. Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth. Molecular Endocrinology. 2010; 24:953-968.
19. Budczies J, Pfitzner BM, Györffy B, Winzer KJ, Radke C, Dietel M, Fiehn O and Denkert C. Glutamate enrichment as new diagnostic opportunity in breast cancer. International Journal of Cancer. 2015; 136:1619-1628.
20. Mazar J, Zhao W, Khalil AM, Lee B, Shelley J, Govindarajan SS, Yamamoto F, Ratnam M, Aftab MN and Collins S. The functional characterization of long noncoding RNA SPRY4-IT1 in human melanoma cells. Oncotarget. 2014; 5:8959. doi: 10.18632/oncotarget.1863.
21. Caiazza F, McCarthy NS, Young L, Hill AD, Harvey BJ and Thomas W. Cytosolic phospholipase A2-a expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. British journal of cancer. 2011; 104:338-344.
22. Togashi Y, Arao T, Kato H, Matsumoto K, Terashima M, Hayashi H, de Velasco MA, Fujita Y, Kimura H and Yasuda T. Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production. Oncotarget. 2014; 5:2962. doi: 10.18632/oncotarget.1561.
23. Budczies J, Brockmöller SF, Müller BM, Barupal DK, Richter-Ehrenstein C, Kleine-Tebbe A, Griffin JL, Orešic M, Dietel M and Denkert C. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. Journal of proteomics. 2013; 94:279-288.
24. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO and Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. Journal of Clinical Oncology. 2010; 28:1684-1691.
25. Trushina E, Dutta T, Persson X-MT, Mielke MM and Petersen RC. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. Plos One, 2013; 8: e63644.